Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

insulin degludec

- PMLiVE

Pfizer builds gap between pharma and consumer health units

Its consumer health division will become a standalone unit after lack of buyer interest

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

- PMLiVE

Novo’s diabetes pill defeats Merck’s Januvia in trial

Oral semaglutide also outshines its best-selling diabetes injectable Victoza

- PMLiVE

Commentary: Roseanne’s racist tweet and Sanofi’s swift and surprising riposte

Alexander Davies considers the remarkable story of how one company broke with pharma convention to speak out on social media

Sanofi reception

Sanofi poaches Peugeot’s finance head

Jean-Baptiste Chasseloup de Chatillon joins the French drugmaker as chief financial officer

- PMLiVE

Evotec says Sanofi deal makes it anti-infectives powerhouse

Aims to inject biotech nimbleness into anti-infectives portfolio

- PMLiVE

AbbVie, Roche get FDA OK for broader use of Venclexta

The drug is tipped to become a $2.5bn product by 2024

Lars Rebien Sørensen becomes chairman of Novo Holdings

He will take up the new role 1 July

- PMLiVE

Daily Brief: AstraZeneca’s new San Fran home, Keytruda triumphs again, Novo branches out

A rapid round up from pharma, biotech and healthcare

- PMLiVE

FDA starts review of Sanofi’s oral type 1 diabetes drug

The US regulator has started its review of Sanofi and Lexicon Pharma’s sotagliflozin for type 1 diabetes, which the firms say could have blockbuster potential.Sotagliflozin – which has the proposed...

- PMLiVE

Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer

Company has reached milestone in stem cell therapy as it looks to broaden range beyond diabetes

- PMLiVE

Regeneron’s Dupixent and Praluent falls short

But CEO Len Schleifer says there’s time to fix that

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links